Johnson & Johnson, the pharmaceutical giant, said yesterday it is five months away from starting human trials on a COVID-19 vaccine that would be offered
Tag: CRISPR
Gene-editing break-through: can a collision of science, ethics and (patent) ownership be avoided?
The USPTO decided in February that the rightful intellectual property owner of CRISPR in eukaryotes, a time-saving tool that makes it cheaper and easier to
